MRK

Merck & Co., Inc.

Next est. report 2026-10-29 · BMO

Biotech '26: Established PharmaChild Care '24: Child Vaccines

Loading…

Loading chart…

Overview

Merck & Co., Inc. is a global healthcare leader with Pharmaceutical and Animal Health divisions. The Pharmaceutical segment, generating over half of revenue, of

Merck & Co., Inc. is a global healthcare leader with Pharmaceutical and Animal Health divisions. The Pharmaceutical segment, generating over half of revenue, offers medicines for oncology, cardiovascular, immunology, and vaccines for human health. The Animal Health segment provides veterinary medications and health solutions. They sell to wholesalers, pharmacies, hospitals, government, managed care, physicians, veterinarians, and livestock producers.

Search Keywords Brand Product

KEYTRUDA
LIPFENDRA
sac-TMT
tulisokibart
IDVYNSO
WELIREG
GARDASIL
CAPVAXIVE
WINREVAIR
OHTUVAYRE
MK-4208
Alimatravir
islatravir
lenacapavir
oncology pipeline
oral PCSK9 inhibitor
TROP2-directed ADC
HIV treatment
immunology therapies
animal health products
vaccine development
cardiometabolic drugs
patent expiration strategy

Search Keywords Event Phrases

Merck earnings call
Q2 2026 results
LIPFENDRA launch
sac-TMT Phase III results
tulisokibart ATLAS-UC trial
AIDS 2026 Congress
ESMO investor event

Search Keywords Policy Regulatory

FDA approval
National Priority Voucher
drug pricing
reimbursement policies

What They Do (Plain English & Analogies): Merck & Co., Inc. is like a big pharmacy and animal doctor rolled into one. For people, they discover, develop, and sell a wide range of medicines and vaccines to treat serious illnesses like cancer, HIV, heart problems, and infectious diseases, and to prevent others, such as HPV. Think of them as a major innovator constantly working in their labs to find new ways to fight diseases and improve health. For animals, they provide medicines, vaccines, and health solutions, similar to how a vet cares for pets and livestock. They sell their products to various healthcare providers, hospitals, and even directly to veterinarians and farmers globally.
Very Brief History: Merck & Co., Inc. was established in 1891 as the American subsidiary of a German pharmaceutical company. However, it became an independent American company in 1917 after being expropriated by the U.S. government during World War I. Since then, it has grown into a global healthcare leader with a strong focus on research and development, particularly in pharmaceuticals and animal health.
"Street Stereotype": Merck is generally perceived by investors and analysts as an established pharmaceutical giant with a robust and diversifying pipeline, particularly in oncology, that is working to navigate the upcoming patent expiration of its blockbuster drug, KEYTRUDA. The market is focused on the success of its new product launches and pipeline advancements to drive long-term growth and offset potential revenue dips post-KEYTRUDA's loss of exclusivity.
Subsidiaries On Linked In*: MSD Animal Health — Global animal health business unit of Merck & Co., Inc. (known as MSD outside the U.S. and Canada).; LinkedIn: MSD Animal Health
Customer Sectors & Example Clients: Merck's customers span various sectors within healthcare and animal health. These include drug wholesalers, pharmacies, hospitals, and government agencies. They also serve managed healthcare organizations, such as health maintenance organizations (HMOs) and pharmacy benefit managers, as well as other institutional clients. Additionally, they supply products to individual physicians and their distributors, veterinarians, and livestock producers.
New Customers / Segments They'Re Targeting: Merck is actively targeting new patient populations and expanding into new segments with its innovative products. For example, with LIPFENDRA, they are aiming to reach a broader patient population with hypercholesterolemia, particularly those who are not at their recommended LDL levels or are untreated, by offering the first oral PCSK9 inhibitor. In oncology, they are expanding KEYTRUDA's use into earlier-stage cancers and new combinations. They are also re-entering the HIV field with new therapies like IDVYNSO and investigational once-monthly oral HIV prep candidates, targeting both virologically suppressed adults and those at risk of HIV.
Supply Chain And Sourcing Geographies: Merck's manufacturing operations are headquartered in Whitehouse Station, New Jersey, USA. The company has human health product manufacturing facilities at nine locations across the United States and Puerto Rico. Internationally, they own or have interests in manufacturing plants in Japan, Singapore, South Africa, and other countries in Western Europe, Central and South America, and Asia. Merck is actively bolstering its global supply chain by expanding manufacturing operations in China and India, focusing on local sourcing of critical raw materials like active pharmaceutical ingredients (APIs). Key investments include vaccine production in Durham, North Carolina; biologics and antibody-drug conjugate manufacturing in Wilmington, Delaware; Animal Health manufacturing in De Soto, Kansas; and pharmaceutical manufacturing (API and drug product) in Elkton, Virginia.
Sales Geographies And Expansion Plans: Merck sells its products globally. The company has strong sales in international markets for products like GARDASIL and CAPVAXIVE. They are progressing with ongoing launches for WINREVAIR outside the U.S. and have regulatory reviews underway for LIPFENDRA in the European Union and China. Merck's operations outside the United States (e.g., in Latin America, the Middle East, Africa, Eastern Europe, and Asia-Pacific) account for a significant portion of its sales.
How Key Themes May Help/Hurt: The 'Biotech '26: Established Pharma' theme presents a mixed outlook for Merck. **Help:** Merck benefits from the theme's bullish drivers, including leveraging cutting-edge research in genomics and personalized medicine (evident in their oncology pipeline and ADCs), and a robust pipeline for high-margin opportunities (e.g., rare disease treatments, new therapies in cardiometabolic and HIV). Strategic partnerships and acquisitions, like the Terns Pharmaceuticals deal, align with the theme's positive aspect of expanding portfolios and research capabilities. **Hurt:** The company faces headwinds from intensifying biosimilar competition (though less directly for its current blockbusters, the broader industry trend is a risk), persistent reimbursement challenges, and regulatory uncertainties, which are key bear points for established pharma. The upcoming patent expiration of KEYTRUDA is a significant challenge that Merck is actively working to mitigate through new launches and pipeline advancements.

3 Main Long-Term Bull Details

Robust and Diversifying Pipeline: Merck has over 20 new products with greater than $70 billion in commercial opportunity, with many programs showing positive clinical readouts faster than expected, significantly de-risking future growth drivers beyond KEYTRUDA.
Leadership in Key Therapeutic Areas: Continued strength in Oncology with KEYTRUDA's expanded indications and new assets like WELIREG and sac-TMT, coupled with re-entry into the HIV field and significant advancements in cardiometabolic and immunology, positions Merck for sustained growth.
Strategic Capital Allocation and Business Development: Disciplined approach to capital allocation, including strategic acquisitions like Terns Pharmaceuticals, allows Merck to augment its portfolio with promising late-stage growth opportunities and enhance long-term shareholder value.

3 Main Long-Term Bear Details

KEYTRUDA Loss of Exclusivity (LOE): The impending patent expiration of KEYTRUDA around 2028 poses a significant challenge, potentially leading to a shallow dip in earnings, despite efforts to diversify the portfolio.
Intensifying Competition: Increased competition from emerging biotech companies and generic drug manufacturers, particularly in mature markets or for products nearing patent expiry, could erode market share and pressure pricing strategies.
Regulatory and Reimbursement Challenges: Regulatory uncertainties and potential shifts in healthcare policies globally could impact drug approval timelines, market access, and reimbursement rates, posing risks to revenue growth and profitability.

Competitors And Differentiation: Merck competes with other major pharmaceutical companies across its therapeutic areas. In oncology, competitors include companies with other TROP2 ADCs and PD-1 inhibitors (e.g., Bristol Myers Squibb with Opdivo). In HIV, Gilead Sciences, Inc. is a collaborator but also a competitor. In cardiometabolic, they compete with existing statins and injectable PCSK9 inhibitors. Merck differentiates itself through: 1. **Innovation and First-in-Class Therapies:** Launching products like LIPFENDRA, the first oral PCSK9 inhibitor, and developing potential first-in-class oral once-weekly HIV treatments. 2. **Broad and Deep Pipeline:** Advancing a diverse pipeline with multiple potential blockbuster opportunities across various therapeutic areas. 3. **Strategic Business Development:** Augmenting its portfolio through disciplined acquisitions like Terns Pharmaceuticals to strengthen its hematology pipeline. 4. **Established Leadership:** Leveraging the enduring strength of its oncology portfolio, particularly KEYTRUDA, and its Animal Health business.
Recent Performance & What The Market'S Focused On: Merck delivered strong second-quarter 2026 revenue of $16.6 billion, an increase of 5% (4% excluding foreign exchange), driven by continued strength in Oncology and Animal Health, and increasing contributions from recent launches. Despite a reported loss of $0.13 per share due to a one-time charge of $2.31 per share from the acquisition of Terns Pharmaceuticals, the company raised and narrowed its full-year revenue guidance to between $66.3 billion and $67.3 billion. The market is primarily focused on the successful execution of its strategy to navigate the KEYTRUDA LOE period, the continued strong performance and adoption of new product launches like WINREVAIR, CAPVAXIVE, WELIREG, LIPFENDRA, and IDVYNSO, and the rapid pace of clinical derisking across its pipeline.

Revenue Segments And Estimated Mix: Oncology (KEYTRUDA family) — Mix: ~50.6%; Source: Q2 2026 transcript; Trend: Increased 4% to $8.4 billion, driven by strong uptake in earlier-stage cancers and continued robust demand from metastatic indications.
Oncology (Broader portfolio, e.g., WELIREG) — Mix: ~1.6%; Source: Q2 2026 transcript; Trend: WELIREG sales increased 67% to $271 million.
Vaccines (GARDASIL) — Mix: ~7.2%; Source: Q2 2026 transcript; Trend: Increased 3% to $1.2 billion, with international growth offsetting flat U.S. sales.
Vaccines (CAPVAXIVE) — Mix: ~1.1%; Source: Q2 2026 transcript; Trend: Increased 40% to $184 million, driven by international launches and higher U.S. demand.
Cardiometabolic and Respiratory (WINREVAIR) — Mix: ~3.5%; Source: Q2 2026 transcript; Trend: Increased 75% to $588 million, reflecting strong demand.
Cardiometabolic and Respiratory (OHTUVAYRE) — Mix: ~1.2%; Source: Q2 2026 transcript; Trend: Sales of $204 million, reflecting continued prescription demand.
Animal Health — Mix: n/m (solid growth); Source: Q2 2026 transcript; Trend: Sales increased 5%, with livestock up 6% and companion animal up 5%.
Other (including IDVYNSO, LIPFENDRA, etc.) — Mix: Remaining portion; Source: Q2 2026 transcript; Trend: Increasing contributions from recent launches like IDVYNSO and LIPFENDRA.
Product Brands: KEYTRUDA
KEYTRUDA QLEX
LIPFENDRA
sac-TMT
tulisokibart
islatravir
lenacapavir
IDVYNSO
Alimatravir
MK-4208
WELIREG
GARDASIL
CAPVAXIVE
WINREVAIR
OHTUVAYRE
MK-1406
ulonivirine
remigromig
MK-3000
LENVIMA
I-DXd
BRIDION

Bull / Bear Details

Merck & Co. is poised for sustained growth driven by a rapidly advancing and diversifying pipeline, including significant new product launches like LIPFENDRA an

Thesis

Merck & Co. is poised for sustained growth driven by a rapidly advancing and diversifying pipeline, including significant new product launches like LIPFENDRA and sac-TMT, which are derisking faster than expected. While facing eventual KEYTRUDA LOE and competitive pressures, strategic business development and strong performance in oncology and animal health underpin a confident outlook for long-term value creation. (Updated August 30, 2026)

Bull case

Merck's pipeline is delivering significant clinical derisking faster than anticipated, with over $70 billion in commercial opportunity from 20+ new products. Recent successes include FDA approval of LIPFENDRA (oral PCSK9 inhibitor), expanded indications for KEYTRUDA and WELIREG, and positive Phase III results for sac-TMT (TROP2 ADC) and tulisokibart (anti-TL1A mAb), bolstering future growth prospects.
The company continues to demonstrate strong commercial execution in its core segments. Oncology sales, driven by the KEYTRUDA family ($8.4 billion, +4%) and WELIREG (+67%), remain robust. The Animal Health business also delivered solid growth (+5%). These established revenue streams provide a stable foundation and significant capital for ongoing innovation and pipeline investments.
Merck's strategic diversification and confident outlook for navigating the KEYTRUDA LOE period are key strengths. Management anticipates a "shallow dip with a fast return to growth," aspiring to grow through it on a non-risk-adjusted basis. Disciplined business development, exemplified by the Terns Pharmaceuticals acquisition, further strengthens the pipeline and long-term growth trajectory.

Bear case

The moderation of total U.S. KEYTRUDA year-over-year growth as it reaches peak penetration in several key indications, coupled with the eventual loss of exclusivity (LOE), presents a significant revenue challenge. While new products are emerging, successfully offsetting this decline will require sustained, high-volume commercial success across multiple new therapies.
The company experienced a decrease in gross margin due to higher inventory reserves and incurred a substantial one-time charge of $5.7 billion for the Terns Pharmaceuticals acquisition, leading to a significantly elevated tax rate of 160.3% for the quarter. These financial impacts highlight potential earnings volatility from operational factors and large-scale business development.
Despite new product launches, Merck faces ongoing challenges in market access and competition. Establishing broad access and reimbursement for therapies like LIPFENDRA will take time, and competition from emerging biotech and generic manufacturers (e.g., BRIDION) can erode market share and pressure pricing, especially in a landscape moving towards combination therapies in immunology.

Bull / Bear Case

No data for this section.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Tulisokibart (anti-TL1A mAb) ATLAS-UC Second Readout and HS Phase II Data Presentation	Tulisokibart is a key immunology pipeline asset with potential across multiple immune-mediated inflammatory conditions. Positive data from these studies would expand its addressable market and reinforce Merck's strategy to bring forward new growth drivers.	The upcoming second readout from the ATLAS-UC trial (induction and maintenance study) for ulcerative colitis and the presentation of data from the Phase II hidradenitis suppurativa (HS) study, both anticipated in the second half of 2026.	Positive results from the ATLAS-UC maintenance study (demonstrating sustained efficacy) and favorable data from the HS study would be bullish signals, indicating broader potential for tulisokibart. Negative or mixed results would be bearish.	Merck's press releases, upcoming scientific congresses (e.g., gastroenterology or dermatology conferences), and clinical trial databases (ClinicalTrials.gov).	Medical conference agendas and abstracts, immunology-focused industry news.	EvaluatePharma: Tulisokibart pipeline progress and sales forecasts.
LIPFENDRA Commercial Uptake and Access Expansion	LIPFENDRA, as the first oral PCSK9 inhibitor, represents a significant new growth driver for Merck, targeting a large unmet need in cardiovascular disease. Its successful launch and broad patient access are crucial for achieving blockbuster potential and diversifying revenue streams.	Monitor LIPFENDRA sales figures, patient prescription trends, progress on access and reimbursement, and the timing of its availability on TrumpRx. Look for commentary on market expansion beyond current injectable PCSK9 users.	Strong initial sales and rapid expansion of patient access and reimbursement, particularly in the primary care setting, would be a bullish signal. Slower than expected uptake or significant access hurdles would be a bearish signal.	Merck's quarterly earnings calls and financial reports, company press releases, and updates on the TrumpRx platform. The next earnings call will provide Q3 2026 sales data.	Google Trends: 'LIPFENDRA', 'oral PCSK9 inhibitor' search volume. FDA website for any post-market updates.	IQVIA/Symphony Health: LIPFENDRA new prescriptions and market share data.
KEYTRUDA QLEX Adoption Rate and U.S. Growth Moderation	KEYTRUDA is Merck's flagship product. While overall U.S. growth is expected to moderate due to peak penetration, the successful adoption of KEYTRUDA QLEX (subcutaneous formulation) is vital for managing the transition and sustaining revenue through the LOE period.	KEYTRUDA QLEX sales figures and adoption trends in subsequent quarterly earnings reports. Monitor the overall year-over-year growth rate of KEYTRUDA in the U.S. and management commentary on the pace of moderation.	Strong and accelerating adoption of KEYTRUDA QLEX, effectively mitigating the moderation of overall U.S. KEYTRUDA growth, would be a bullish signal. Slower-than-expected QLEX uptake or a steeper decline in overall U.S. KEYTRUDA sales would be a bearish signal.	Merck's quarterly earnings calls and financial reports. The next earnings call will provide Q3 2026 sales data.	Google Trends: 'KEYTRUDA QLEX' search volume, physician forums discussing new oncology formulations.	IQVIA/Symphony Health: KEYTRUDA QLEX prescription data and market share.
Sac-TMT (TROP2-directed ADC) TroFuse-005 Detailed Data Presentation and Regulatory Filing	Sac-TMT is a cornerstone ADC with significant blockbuster potential, expected to transform Merck's oncology portfolio. The detailed data presentation and subsequent regulatory filing are critical steps in derisking this asset and validating its commercial opportunity.	Detailed results of the Phase III TroFuse-005 study in advanced or recurrent endometrial cancer at the ESMO investor event on Monday, October 26, 2026. Also, watch for the timing and acceptance of the regulatory filing, which Merck plans to expedite using a National Priority Review Voucher.	Presentation of robust, clinically meaningful detailed data at ESMO and a swift, successful regulatory filing for endometrial cancer would be a strong bullish signal. Any unexpected safety concerns or delays in filing would be bearish.	Merck's investor event at ESMO on October 26, 2026, company press releases, and the FDA's new drug application tracking. ESMO Congress 2026 is from October 23-27, 2026, in Madrid, Spain.	ESMO Congress 2026 abstracts and presentations (available post-event), oncology-focused news outlets (e.g., Fierce Pharma, Endpoints News).	EvaluatePharma: Sac-TMT pipeline valuation and probability of success updates.
WINREVAIR Label Update PDUFA Date	WINREVAIR is a growing product in pulmonary arterial hypertension (PAH). A label update based on the HYPERION study could expand its approved indications or patient population, further driving sales growth and strengthening its market position.	The FDA's decision on the WINREVAIR label update based on the Phase III HYPERION study, with a PDUFA date of September 21, 2026.	FDA approval of the label update would be a bullish signal, indicating expanded market potential. A delay or rejection would be a bearish signal.	FDA website (Prescription Drug User Fee Act (PDUFA) dates), Merck's press releases, and regulatory news services.	FDA drug approval announcements, industry news sites covering regulatory decisions.	Citeline: Regulatory intelligence for WINREVAIR.

Key Reported Metrics, Reratings Triggers & Results3 rows

WINREVAIR is a significant new growth driver with strong demand. Continued high growth rates will demonstrate the successful commercialization of new products a

Upcoming print · 2026-10-29

Key reported metrics
Metric	Last period	Why it matters
WINREVAIR Sales	75%	WINREVAIR is a significant new growth driver with strong demand. Continued high growth rates will demonstrate the successful commercialization of new products and diversification beyond oncology.
KEYTRUDA Family Sales	4%	KEYTRUDA remains a cornerstone product. Its sales performance, especially the adoption of KEYTRUDA QLEX, is critical for mitigating the anticipated moderation of U.S. growth and sustaining oncology leadership.
Total Revenue	5%	Total Revenue indicates the overall financial health and growth trajectory of Merck, reflecting the combined performance of its diverse pharmaceutical and animal health portfolios. Investors will watch for sustained growth.

Key Questions

Will the initial commercial uptake and broad market access for the newly launched oral PCSK9 inhibitor, LIPFENDRA, meet or exceed Merck's expectations for marke

Will the initial commercial uptake and broad market access for the newly launched oral PCSK9 inhibitor, LIPFENDRA, meet or exceed Merck's expectations for market expansion, validating its blockbuster potential in the coming quarters?

Question 2: How will the detailed Phase III TroFuse-005 data for sac-TMT in endometrial cancer, and Merck's refined strategy for sac-TMT in first-line lung cancer, impact investor confidence in its ability to drive significant oncology growth post-KEYTRUDA?
Question 3: Will the upcoming full ATLAS-UC data for tulisokibart in ulcerative colitis and the Phase II hidradenitis suppurativa (HS) data further solidify the drug's competitive profile and expand confidence in Merck's broader immunology pipeline?

Earnings Transcript SummaryTable

2026-08-04 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Advancing and diversifying the pipeline: Management highlighted the substantial progress across the business, driven by growing contributions from new product launches and the continued advancement of over 20 new products from their pipeline, representing greater than $70 billion in commercial opportunity. They emphasized meaningful advancements against clinical milestones, with several proof points occurring earlier than expected. 2. Maximizing KEYTRUDA's potential and expanding oncology leadership: Management reiterated their strategy to maximize the transformative potential of KEYTRUDA and expand, deepen, and extend their leadership in Oncology, citing ongoing approvals and compelling clinical data for KEYTRUDA and its combinations. 3. Disciplined business development and capital allocation: Management underscored their commitment to disciplined business development, exemplified by the acquisition of Terns Pharmaceuticals, adding MK-4208 to strengthen their hematology pipeline. They also emphasized prioritizing investments that support near- and long-term growth, including new product launches and the robust pipeline, while maintaining a commitment to the dividend and share repurchases.	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management expressed strong satisfaction with the substantial progress across the business, driven by robust execution, growing contributions from new product launches, and accelerated pipeline advancements. They highlighted significant clinical derisking events occurring faster than expected, reinforcing their confidence in Merck's future growth trajectory, particularly through the KEYTRUDA LOE period, which they anticipate as a 'shallow dip with a fast return to growth.' The tone was optimistic, emphasizing the strength of their science, disciplined capital allocation, and commitment to delivering long-term value for patients and shareholders.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 5% (3% ex-FX). Oncology (KEYTRUDA family sales): 8% (ex-FX). WELIREG sales: 43%. GARDASIL sales: -22%. CAPVAXIVE sales: Not explicitly mentioned in prior quarter's earnings summary from search results. WINREVAIR sales: 87% (ex-FX). OHTUVAYRE sales: Not explicitly mentioned in prior quarter's earnings summary from search results. Animal Health sales: 6% (ex-FX). Livestock sales: Not explicitly mentioned in prior quarter's earnings summary from search results. Companion animal sales: Not explicitly mentioned in prior quarter's earnings summary from search results.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Sac-TMT development strategy and combination trials: Analysts inquired about the potential for broad sac-TMT plus pembro trials against KEYNOTE-189 and sac-TMT combos with PD-1/VEGF for first-line lung cancer. Management responded positively, stating they are rethinking KEYNOTE-189 with sac-TMT as a next-gen chemo and are moving fast to initiate trials, including optimizing combinations with IO agents like KEYTRUDA or MK-2010. 2. TL1A activity and fibrosis opportunity: Analysts pressed on whether TL1A activity in new indications like HS is beyond TNF expectations and how the negative SSc-ILD study impacts the fibrosis opportunity. Management highlighted the positive HS readout, increasing confidence in derm possibilities, and noted clear biomarker data for rheumatoid arthritis. Regarding SSc-ILD, they explained it's a challenging disease where no anti-cytokine has worked, and the study's outcome doesn't necessarily negate the immunofibrosis hypothesis, especially if the placebo arm showed no progression. 3. LIPFENDRA launch, access, and combination strategies: Analysts questioned the pace of initial access and reimbursement expectations for LIPFENDRA, its potential for injectable PCSK9 switch versus naive patients, and combination approaches. Management expressed pleasure with initial interest, expecting a slower but long-term blockbuster trajectory due to the need to establish broad access. They emphasized market expansion for the 30 million untreated or sub-optimally treated patients, not just taking share from injectables. They also discussed combination plans with rosuvastatin (aiming for up to 80% LDL reduction) and an Lp(a) inhibitor, and noted they are not actively pursuing GLP-1 combinations in clinical trials yet.	Revenue SegmentsTotal company revenues increased 5% (4% excluding the impact of foreign exchange). Sales of the KEYTRUDA family of products increased 4% to $8.4 billion (ex-exchange basis). WELIREG sales increased 67% to $271 million. GARDASIL sales were $1.2 billion, an increase of 3%. CAPVAXIVE sales were $184 million, an increase of 40%. WINREVAIR global sales were $588 million, an increase of 75%. OHTUVAYRE sales were $204 million. Animal Health business sales increased 5%. Livestock sales grew 6%. Companion animal sales increased 5%.

Transcript TidbitsTable

2026-08-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketMerck sees a greater than $70 billion commercial opportunity from over 20 new products expected to transform its portfolio and fuel growth well into the next decade. The FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, to reduce LDL cholesterol in adults with hypercholesterolemia, with Merck aiming for broad patient access to address elevated LDL-C. KEYTRUDA continues to show strong uptake in earlier-stage cancers and robust demand in metastatic indications, particularly in tumors affecting women and in combination with Padcev for urothelial cancer. WELIREG received FDA approval for adjuvant treatment in certain patients with earlier-stage renal cell carcinoma. IDVYNSO, a once-daily oral HIV treatment, is seeing encouraging early progress on access and reimbursement, with plans to broaden access over time. WINREVAIR global sales increased 75% due to continued strong demand from adults with pulmonary arterial hypertension, with over 1,800 new U.S. patients receiving prescriptions. Alimatravir, an investigational once-monthly oral HIV prep candidate, is in Phase III studies, with initial access plans announced to enable broad and sustainable access upon potential approval. LIPFENDRA has the potential to extend PCSK9 inhibition globally, with regulatory reviews underway in the European Union and China. Merck is not focused on taking share from injectable PCSK9 inhibitors, which reach less than 5% of the market, but rather on expanding the market of 30 million people in the U.S. who are not at recommended LDL levels or are untreated for cardiovascular disease. New guidelines from the American Heart Association and American College of Cardiology recommend LDL levels below 55 for the vast majority of secondary ASCVD patients, supporting the need for therapies like LIPFENDRA.	About CompetitionU.S. sales for BRIDION are expected to decline at a slower pace than previously anticipated due to lower-than-expected generic competition. For sac-TMT, Merck aims for differentiation in breast and lung cancer given other TROP2 ADCs in development. Merck is not focusing on taking market share from injectable PCSK9 inhibitors with LIPFENDRA, but rather on expanding the overall market. The immunology field is moving towards combination therapies, and Merck is evaluating ideal combinations for its TL1A program across different indications, leveraging its clean safety profile.	About The Broader IndustryCardiovascular disease remains the #1 silent killer in the United States. The FDA is using LIPFENDRA as a cornerstone to demonstrate its priority review process, focusing on public health crises, innovative breakthroughs, large unmet needs in chronic disease, onshoring and supply chain resilience, and increasing accessibility. The entire immunology field is actively exploring combination approaches for treatments.	Where Things Are HeadedMerck expects its new products to fuel growth well into the next decade. The company remains confident in its outlook for the remainder of the year and the trajectory of KEYTRUDA QLEX adoption. Merck anticipates accelerated growth for OHTUVAYRE in 2027 following investments in its sales force and efforts to improve patient experience. Total U.S. KEYTRUDA year-over-year growth is expected to moderate as it reaches peak penetration in several key indications. Business development remains a high priority, with Merck maintaining the ability to pursue additional science-driven, value-creating transactions. The company is on pace for approximately $3 billion in share repurchases this year. Merck expects a shallow dip in earnings during the KEYTRUDA LOE period, followed by a fast return to growth, aspiring to grow through it on a non-risk-adjusted basis. Merck is advancing combination approaches for LIPFENDRA, including fixed-dose combinations with rosuvastatin and MK-7262 (oral Lp(a) inhibitor). The HIV pipeline aims to address unmet needs with novel oral options, including two once-weekly treatment regimens and a monthly oral option for pre-exposure prophylaxis. Merck plans to advance ISL/ULO into Phase III studies for previously untreated and treated HIV patients. The monthly oral HIV prep option, alimatravir, is in two Phase III studies with readouts anticipated next year. The long-acting strain-agnostic influenza antiviral, MK-1406, remains on track for potential approval in 2029. Merck anticipates a busy second half of the year with multiple events and milestones, including a PDUFA date for WINREVAIR, additional tulisokibart data, remigromig data in ophthalmology, and potential approvals for WELIREG plus LENVIMA and I-DXd in oncology.	Updates On ThemeEstablished	Bullish-Leaning Quotes (Short)I remain very pleased with the substantial progress we're making across our business. This progress further bolsters my high confidence in the future of our company. I believe Merck is substantially stronger, more diversified and better positioned for sustainable growth than it was just 5 years ago. We remain confident in the outlook of our business. My confidence is higher than it was in January because we are seeing meaningful derisking.	Bearish-Leaning Quotes (Short)Gross margin was 81.1%, a decrease of 1.1 percentage points, primarily due to higher inventory reserves. There was a $5.7 billion charge for the acquisition of Terns Pharmaceuticals in the quarter. Total U.S. KEYTRUDA year-over-year growth will moderate as we increasingly reach peak penetration across several key indications. Third quarter sales will be impacted by the unwind of specialty pharmacy purchases in the second quarter. Our tax rate was 160.3%.	HiringMerck continues to invest behind its sales force and promotion to reach more physicians and patients in the U.S. for OHTUVAYRE.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-04	Merck reported strong Q2 2026 results, driven by oncology and new launches, and raised full-year revenue guidance. Pipeline derisking, including positive sac-TMT and tulisokibart data, bolstered management's bullish outlook despite a Terns acquisition charge. The stock initially underperformed the market (t+2 days), contradicting the positive messaging. However, subsequent significant outperformance suggests the market later embraced Merck's diversified pipeline and long-term growth strategy.	Earnings Transcript	Neutral		+0.47% (vs SPY: -0.97%)

Upcoming EventsTable

No data for this section.